EMERGENT BIOSOLUTIONS INC. Cash and Restricted Cash
EMERGENT BIOSOLUTIONS INC. (EBS) had Cash and Restricted Cash of $140.90 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $140.90M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $161.50M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $209.10M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $249.20M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $140.90M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $161.50M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $209.10M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $249.20M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $271.00M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $152.80M 10-Q · filed 2026-05-01 | |
| 2024-12-31 | $105.60M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $156.40M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $71.00M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $79.00M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $111.70M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $87.80M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $88.60M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $430.20M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $642.60M 10-K · filed 2026-02-27 | |
| 2022-09-30 | $241.00M 10-Q · filed 2023-12-11 | |
| 2022-06-30 | $358.30M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $436.00M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $576.30M 10-K · filed 2025-03-04 | |
| 2021-09-30 | $404.00M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $447.70M 10-Q · filed 2022-08-02 | |
| 2021-03-31 | $548.00M 10-Q · filed 2022-04-29 | |
| 2020-12-31 | $621.50M 10-K · filed 2024-03-08 | |
| 2020-09-30 | $415.20M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $269.00M 10-Q · filed 2021-07-30 | |
| 2020-03-31 | $181.70M 10-Q · filed 2021-04-30 | |
| 2019-12-31 | $168.00M 10-K/A · filed 2023-12-11 | |
| 2019-09-30 | $139.40M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $177.60M 10-Q · filed 2020-07-31 | |
| 2019-03-31 | $137.40M 10-Q · filed 2020-05-01 | |
| 2018-12-31 | $112.40M 10-K · filed 2022-02-25 | |
| 2018-09-30 | $340.40M 10-Q · filed 2019-11-07 | $340.40M 10-Q · filed 2018-11-02 |
| 2018-06-30 | $191.30M 10-Q · filed 2019-08-02 | $191.28M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $164.60M 10-Q · filed 2019-05-08 | $164.65M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $179.30M 10-K · filed 2021-02-19 | $179.34M 10-Q · filed 2018-05-04 |
| 2017-09-30 | $340.99M 10-Q · filed 2018-11-02 | |
| 2017-06-30 | $315.63M 10-Q · filed 2018-08-03 | |
| 2017-03-31 | $270.17M 10-Q · filed 2018-05-04 | |
| 2016-12-31 | $272.50M 10-K · filed 2020-02-25 | $271.51M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |